Clinical Trial Update: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating suppression of the PI3K/Akt pathway in glioblastoma and gliosarcoma, compared with pembrolizumab (MK-3475).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Medical Research Council | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: UNKNOWN